Do analysts prefer PDSB or PHXM?

PDS Biotechnology currently has a consensus price target of $9.00, suggesting a potential upside of 1,220.81%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, equities analysts plainly believe PDS Biotechnology is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, PDSB or PHXM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is PDSB or PHXM more profitable?

PHAXIAM Therapeutics' return on equity of 0.00% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets PDS Biotechnology N/A -346.02% -102.36% PHAXIAM Therapeutics N/A N/A N/A

Do analysts prefer PHXM or RNXT?

RenovoRx has a consensus target price of $8.50, indicating a potential upside of 882.32%. Given RenovoRx's stronger consensus rating and higher probable upside, analysts clearly believe RenovoRx is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 RenovoRx 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has preferable earnings & valuation, PHXM or RNXT?

PHAXIAM Therapeutics has higher earnings, but lower revenue than RenovoRx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PHAXIAM Therapeutics N/A N/A -$240K N/A N/A RenovoRx $1.49M 26.18 -$11.17M -$0.33 N/A

Do analysts rate PHXM or NNVC?

NanoViricides has a consensus target price of $6.00, indicating a potential upside of 305.41%. Given NanoViricides' stronger consensus rating and higher probable upside, analysts clearly believe NanoViricides is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger earnings & valuation, PHXM or NNVC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PHAXIAM Therapeutics N/A N/A -$240K N/A N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is PHXM or NNVC more profitable?

PHAXIAM Therapeutics' return on equity of 0.00% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets PHAXIAM Therapeutics N/A N/A N/A NanoViricides N/A -87.90% -78.69%

Which has stronger earnings & valuation, IZTC or PHXM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is IZTC or PHXM more profitable?

Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A PHAXIAM Therapeutics N/A N/A N/A

Do analysts recommend IXHL or PHXM?

Incannex Healthcare currently has a consensus price target of $18.00, suggesting a potential upside of 510.17%. Given Incannex Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe Incannex Healthcare is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, IXHL or PHXM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incannex Healthcare N/A N/A -$46.88M -$1.55 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is IXHL or PHXM more profitable?

PHAXIAM Therapeutics' return on equity of 0.00% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Incannex Healthcare N/A -81.01% -76.11% PHAXIAM Therapeutics N/A N/A N/A

PHAXIAM Therapeutics (PHXM) Competitors

$3.10 0.00 (0.00%)

As of 07/24/2026

Compare

PHXM vs. PDSB, RNXT, NNVC, IZTC, and IXHL

Should you buy PHAXIAM Therapeutics stock or one of its competitors? MarketBeat compares PHAXIAM Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PHAXIAM Therapeutics include PDS Biotechnology (PDSB), RenovoRx (RNXT), NanoViricides (NNVC), Invizyne Technologies (IZTC), and Incannex Healthcare (IXHL). These companies are all part of the "pharmaceutical products" industry.

How does PHAXIAM Therapeutics compare to PDS Biotechnology?

PDS Biotechnology (NASDAQ:PDSB) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

PDS Biotechnology has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market.

PHAXIAM Therapeutics' return on equity of 0.00% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
PHAXIAM Therapeutics	N/A	N/A	N/A

26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 8.4% of PDS Biotechnology shares are held by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, PDS Biotechnology had 2 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for PDS Biotechnology and 0 mentions for PHAXIAM Therapeutics. PDS Biotechnology's average media sentiment score of 1.89 beat PHAXIAM Therapeutics' score of 0.00 indicating that PDS Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
PDS Biotechnology	Very Positive
PHAXIAM Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

PDS Biotechnology currently has a consensus price target of $9.00, suggesting a potential upside of 1,220.81%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, equities analysts plainly believe PDS Biotechnology is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

PDS Biotechnology beats PHAXIAM Therapeutics on 7 of the 11 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to RenovoRx?

PHAXIAM Therapeutics (NASDAQ:PHXM) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

PHAXIAM Therapeutics has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. PHAXIAM Therapeutics' return on equity of 0.00% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
RenovoRx	-823.98%	-135.03%	-101.92%

PHAXIAM Therapeutics has higher earnings, but lower revenue than RenovoRx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
RenovoRx	$1.49M	26.18	-$11.17M	-$0.33	N/A

RenovoRx has a consensus target price of $8.50, indicating a potential upside of 882.32%. Given RenovoRx's stronger consensus rating and higher probable upside, analysts clearly believe RenovoRx is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, RenovoRx had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for RenovoRx and 0 mentions for PHAXIAM Therapeutics. RenovoRx's average media sentiment score of 0.94 beat PHAXIAM Therapeutics' score of 0.00 indicating that RenovoRx is being referred to more favorably in the news media.

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
RenovoRx	Positive

PHAXIAM Therapeutics has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market. Comparatively, RenovoRx has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market.

0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Comparatively, 9.4% of RenovoRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

RenovoRx beats PHAXIAM Therapeutics on 9 of the 14 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to NanoViricides?

PHAXIAM Therapeutics (NASDAQ:PHXM) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

PHAXIAM Therapeutics' return on equity of 0.00% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
NanoViricides	N/A	-87.90%	-78.69%

In the previous week, NanoViricides had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for NanoViricides and 0 mentions for PHAXIAM Therapeutics. PHAXIAM Therapeutics' average media sentiment score of 0.00 beat NanoViricides' score of -0.20 indicating that PHAXIAM Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
NanoViricides	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

PHAXIAM Therapeutics has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market. Comparatively, NanoViricides has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market.

0.4% of PHAXIAM Therapeutics shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by insiders. Comparatively, 3.6% of NanoViricides shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

NanoViricides has a consensus target price of $6.00, indicating a potential upside of 305.41%. Given NanoViricides' stronger consensus rating and higher probable upside, analysts clearly believe NanoViricides is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

NanoViricides beats PHAXIAM Therapeutics on 6 of the 11 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
PHAXIAM Therapeutics	N/A	N/A	N/A

In the previous week, Invizyne Technologies' average media sentiment score of 0.00 equaled PHAXIAM Therapeutics'average media sentiment score.

Company	Overall Sentiment
Invizyne Technologies	Neutral
PHAXIAM Therapeutics	Neutral

Summary

PHAXIAM Therapeutics beats Invizyne Technologies on 2 of the 2 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Incannex Healthcare?

Incannex Healthcare (NASDAQ:IXHL) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

PHAXIAM Therapeutics' return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
PHAXIAM Therapeutics	N/A	N/A	N/A

In the previous week, Incannex Healthcare had 4 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 4 mentions for Incannex Healthcare and 0 mentions for PHAXIAM Therapeutics. Incannex Healthcare's average media sentiment score of 0.22 beat PHAXIAM Therapeutics' score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Incannex Healthcare	Neutral
PHAXIAM Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	N/A	N/A	-$46.88M	-$1.55	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Incannex Healthcare currently has a consensus price target of $18.00, suggesting a potential upside of 510.17%. Given Incannex Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe Incannex Healthcare is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Incannex Healthcare has a beta of 6.95, indicating that its share price is 595% more volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market.

0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Incannex Healthcare beats PHAXIAM Therapeutics on 7 of the 11 factors compared between the two stocks.

Get PHAXIAM Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHXM vs. The Competition

Export

Metric	PHAXIAM Therapeutics	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.58M	$434.82M	$6.87B	$12.26B
Dividend Yield	N/A	3.90%	2.67%	9.79%
P/E Ratio	N/A	3.16	27.14	23.64
Price / Sales	N/A	6,592.20	517.08	89.57
Price / Cash	N/A	13.13	50.54	59.64
Price / Book	0.39	83.70	10.28	6.07
Net Income	-$240K	-$96.07M	$3.60B	$331.99M
7 Day Performance	N/A	-0.66%	-1.27%	-0.63%
1 Month Performance	N/A	-1.07%	-0.37%	-2.00%
1 Year Performance	N/A	56.07%	18.30%	13.62%

PHAXIAM Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49
PDSB PDS Biotechnology	2.4308 of 5 stars	$0.75 +0.9%	$9.00 +1,096.8%	-43.7%	$41.67M	N/A	N/A	20	News Coverage Positive News Analyst Downgrade
RNXT RenovoRx	4.1153 of 5 stars	$0.85 -6.9%	$8.50 +900.0%	-33.4%	$41.15M	$1.12M	N/A	6
NNVC NanoViricides	1.6493 of 5 stars	$1.77 +7.3%	$6.00 +239.0%	-13.5%	$40.68M	N/A	N/A	20
IZTC Invizyne Technologies	N/A	$6.37 -8.6%	N/A	-49.2%	$39.83M	N/A	N/A	29	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHXM) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PHAXIAM Therapeutics (PHXM) Competitors

PHXM vs. PDSB, RNXT, NNVC, IZTC, and IXHL

How does PHAXIAM Therapeutics compare to PDS Biotechnology?

Summary

How does PHAXIAM Therapeutics compare to RenovoRx?

Summary

How does PHAXIAM Therapeutics compare to NanoViricides?

Summary

How does PHAXIAM Therapeutics compare to Invizyne Technologies?

Summary

How does PHAXIAM Therapeutics compare to Incannex Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHXM vs. The Competition

PHAXIAM Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PHAXIAM Therapeutics (PHXM) Competitors

PHXM vs. PDSB, RNXT, NNVC, IZTC, and IXHL

How does PHAXIAM Therapeutics compare to PDS Biotechnology?

Which has more volatility & risk, PDSB or PHXM?

Is PDSB or PHXM more profitable?

Do institutionals & insiders have more ownership in PDSB or PHXM?

Does the media favor PDSB or PHXM?

Which has preferable earnings & valuation, PDSB or PHXM?

Do analysts prefer PDSB or PHXM?

Summary

How does PHAXIAM Therapeutics compare to RenovoRx?

Is PHXM or RNXT more profitable?

Which has preferable earnings & valuation, PHXM or RNXT?

Do analysts prefer PHXM or RNXT?

Does the media refer more to PHXM or RNXT?

Which has more volatility and risk, PHXM or RNXT?

Do institutionals and insiders have more ownership in PHXM or RNXT?

Summary

How does PHAXIAM Therapeutics compare to NanoViricides?

Is PHXM or NNVC more profitable?

Does the media prefer PHXM or NNVC?

Which has stronger earnings & valuation, PHXM or NNVC?

Which has more volatility & risk, PHXM or NNVC?

Do institutionals & insiders hold more shares of PHXM or NNVC?

Do analysts rate PHXM or NNVC?

Summary

How does PHAXIAM Therapeutics compare to Invizyne Technologies?

Do institutionals and insiders believe in IZTC or PHXM?

Which has stronger earnings & valuation, IZTC or PHXM?

Is IZTC or PHXM more profitable?

Does the media favor IZTC or PHXM?

Summary

How does PHAXIAM Therapeutics compare to Incannex Healthcare?

Is IXHL or PHXM more profitable?

Does the media favor IXHL or PHXM?

Which has preferable earnings and valuation, IXHL or PHXM?

Do analysts recommend IXHL or PHXM?

Which has more volatility & risk, IXHL or PHXM?

Do institutionals and insiders have more ownership in IXHL or PHXM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHXM vs. The Competition

PHAXIAM Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools